Fosfomycin versus other antibiotics for the treatment of cystitis: A meta-analysis of randomized controlled trials

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 9, 2010, Pages 1862-1877

  Falagas, Matthew E ^a,b,c   Vouloumanou, Evridiki K ^a   Togias, Antonios G ^a   Karadima, Maria ^a   Kapaskelis, Anastasios M ^a,b   Rafailidis, Petros I ^a,b   Athanasiou, Stavros ^d  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Fosfomycin tromethamine; Microbiological eradication; Pregnancy; Safety

Indexed keywords

AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFALEXIN; CEFTIBUTEN; CEFUROXIME AXETIL; CIPROFLOXACIN; COTRIMOXAZOLE; FOSFOMYCIN; NETILMICIN; NITROFURANTOIN; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; PIPEMIDIC ACID; TRIMETHOPRIM;

AGE DISTRIBUTION; CLINICAL TRIAL; CYSTITIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; META ANALYSIS; MICROBIOLOGY; PEDIATRICS; PREGNANT WOMAN; REVIEW; SEX DIFFERENCE; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; URINARY TRACT INFECTION;

EID: 77955646149     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq237     Document Type: Review

References (55)

1. Foxman B, Barlow R, D'Arcy H et al. Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol 2000; 10: 509-15.
2. Nickel JC, Lee JC, Grantmyre JE et al. Natural history of urinary tract infection in a primary care environment in Canada. Can J Urol 2005; 12: 2728-37.
3. Reeves DS. Fosfomycin trometamol. J Antimicrob Chemother 1994; 34: 853-8.
4. Gupta K. Emerging antibiotic resistance in urinary tract pathogens. Infect Dis Clin North Am 2003; 17: 243-59.
5. Gagliotti C, Buttazzi R, Sforza S et al. Resistance to fluoroquinolones and treatment failure/short-term relapse of community-acquired urinary tract infections caused by Escherichia coli. J Infect 2008; 57: 179-84.
6. Ho PL, Wong RC, Yip KS et al. Antimicrobial resistance in Escherichia coli outpatient urinary isolates from women: emerging multidrug resistance phenotypes. Diagn Microbiol Infect Dis 2007; 59: 439-45.
7. Zahar JR, Lortholary O, Martin C et al. Addressing the challenge of extended-spectrum β-lactamases. Curr Opin Investig Drugs 2009; 10: 172-80.
8. Patel SS, Balfour JA, Bryson HM. Fosfomycin tromethamine: a review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs 1997; 53: 637-56.
9. Roussos N, Karageorgopoulos DE, Samonis G et al. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents 2009; 34: 506-15.
10. Warren JW, Abrutyn E, Hebel JR et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999; 29: 745-58.
11. Falagas ME, Giannopoulou KP, Kokolakis GN et al. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 2008; 46: 1069-77.
12. Falagas ME, Kanellopoulou MD, Karageorgopoulos DE et al. Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin. Eur J Clin Microbiol Infect Dis 2008; 27: 439-43.
13. Falagas ME, Kastoris AC, Karageorgopoulos DE et al. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents 2009; 34: 111-20.
14. Falagas ME, Roussos N, Gkegkes ID et al. Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies. Expert Opin Investig Drugs 2009; 18: 921-44.
15. Nicolle LE, Bradley S, Colgan R et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 2005; 40: 643-54.
16. Rubin RH, Shapiro ED, Andriole VT et al. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; 15 Suppl 1: S216-27.
17. Moher D, Jadad AR, Tugwell P. Assessing the quality of randomized controlled trials. Current issues and future directions. Int J Technol Assess Health Care 1996; 12: 195-208.
18. Moher D, Pham B, Jones A et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352: 609-13.
19. Bozkurt O, Kara C, Akarsu S et al. Comparison efficacy of single dose fosfomycin with ciprofloxacin in the treatment of urinary tract infection in symptomatic women. Turk Uroloji Dergisi 2008; 34: 360-2.
20. Gupta K, Hooton TM, Stamm WE. Isolation of fluoroquinoloneresistant rectal Escherichia coli after treatment of acute uncomplicated cystitis. J Antimicrob Chemother 2005; 56: 243-6.
21. Stein GE. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. Clin Ther 1999; 21: 1864-72.
22. Minassian MA, Lewis DA, Chattopadhyay D et al. A comparison between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women. Int J Antimicrob Agents 1998; 10: 39-47.
23. Richaud C. Le traitement monodose de la cystite non compliquee chez la femme propos d'un essai fosfomycine trometamol (Monurilw) versus pefloxacine. Med Mal Infect 1995; 25: 154-9.
24. Elhanan G, Tabenkin H, Yahalom R et al. Single-dose fosfomycin trometamol versus 5-day cephalexin regimen for treatment of uncomplicated lower urinary tract infections in women. Antimicrob Agents Chemother 1994; 38: 2612-4.
25. Van Pienbroek E, Hermans J, Kaptein AA et al. Fosfomycin trometamol in a single dose versus seven days nitrofurantoin in the treatment of acute uncomplicated urinary tract infections in women. Pharm World Sci 1993; 15: 257-62.
26. Cortes R, Pascual T, Lou Arnal S et al. Single oral dose of phosphomycin trometamol versus pipemidic acid and norfloxacin in treating uncomplicated low-level urinary tract infections. Aten Primaria 1992; 10: 1007-12.
27. de Jong Z, Pontonnier F, Plante P. Single-dose fosfomycin trometamol (Monuril) versus multiple-dose norfloxacin: results of a multicenter study in females with uncomplicated lower urinary tract infections. Urol Int 1991; 46: 344-8.
28. Boerema JB, Willems FT. Fosfomycin trometamol in a single dose versus norfloxacin for seven days in the treatment of uncomplicated urinary infections in general practice. Infection 1990; 18 Suppl 2: S80-8.
29. Crocchiolo P. Single-dose fosfomycin trometamol versus multiple-dose cotrimoxazole in the treatment of lower urinary tract infections in general practice. Multicenter Group of General Practitioners. Chemotherapy 1990; 36 Suppl 1: 37-40.
30. Harvard Davis R, O'Dowd TC, Holmes W et al. A comparative double-blind randomised study of single dose fosfomycin trometamol with trimethoprim in the treatment of urinary tract infections in general practice. Chemotherapy 1990; 36 Suppl 1: 34-6.
31. Naber KG, Thyroff-Friesinger U. Fosfomycin trometamol versus ofloxacin/co-trimoxazole as single dose therapy of acute uncomplicated urinary tract infection in females: a multicentre study. Infection 1990; 18 Suppl 2: S70-6.
32. Neu HC. Fosfomycin trometamol versus amoxycillin-single-dose multicenter study of urinary tract infections. Chemotherapy 1990; 36 Suppl 1: 19-23.
33. Reynaert J, Van Eyck D, Vandepitte J. Single dose fosfomycin trometamol versus multiple dose norfloxacin over three days for uncomplicated UTI in general practice. Infection 1990; 18 Suppl 2: S77-9.
34. Selvaggi FP, Ditonno P, Traficante A et al. Fosfomycin trometamol (Monuril) versus norfloxacin in single dose for adult female uncomplicated UTIs: multicenter randomized, double-blind study. Chemotherapy 1990; 36 Suppl 1: 31-3.
35. Caramalli S, Amprimo MC, Cavalli G et al. Effect and pharmacokinetics of netilmicin given as bolus intramuscular administration: an open comparative trial versus amikacin and fosfomycin in elderly patients affected by urinary tract infections. Int J Clin Pharmacol Res 1991; 11: 55-65.
36. Cooper J, Raeburn A, Brumfitt W et al. Single dose and conventional treatment for acute bacterial and non-bacterial dysuria and frequency in general practice. Infection 1990; 18: 65-9.
37. Ferraro G, Ambrosi G, Bucci L et al. Fosfomycin trometamol versus norfloxacin in the treatment of uncomplicated lower urinary tract infections of the elderly. Chemotherapy 1990; 36 Suppl 1: 46-9.
38. Estebanez A, Pascual R, Gil V et al. Fosfomycin in a single dose versus a 7-day course of amoxicillin-clavulanate for the treatment of asymptomatic bacteriuria during pregnancy. Eur J Clin Microbiol Infect Dis 2009; 28: 1457-64.
39. Bayrak O, Cimentepe E, Inegol I et al. Is single-dose fosfomycin trometamol a good alternative for asymptomatic bacteriuria in the second trimester of pregnancy? Int Urogynecol J Pelvic Floor Dysfunct 2007; 18: 525-9.
40. Krcmery S, Hromec J, Demesova D. Treatment of lower urinary tract infection in pregnancy. Int J Antimicrob Agents 2001; 17: 279-82.
41. Zinner S. Fosfomycin trometamol versus pipemidic acid in the treatment of bacteriuria in pregnancy. Chemotherapy 1990; 36 Suppl 1: 50-2.
42. Thoumsin H, Aghayan M, Lambotte R. Single dose fosfomycin trometamol versus multiple dose nitrofurantoin in pregnant women with bacteriuria: preliminary results. Infection 1990; 18 Suppl 2: S94-7.
43. Principi N, Corda R, Bassetti D et al. Fosfomycin trometamol versus netilmicin in children's lower urinary tract infections. Chemotherapy 1990; 36 Suppl 1: 41-5.
44. Careddu P, Borzani M, Scotti L et al. Treatment of lower urinary tract infections in children: single dose fosfomycin trometamol versus pipemidic acid. Chemioterapia 1987; 6: 290-4.
45. Varese LA. Trometamol salt of fosfomycin versus netilmicin: randomized multicenter study in children's lower urinary tract infections. Eur Urol 1987; 13 Suppl 1: 119-21.
46. Kumon H, Ono N, Iida M et al. Combination effect of fosfomycin and ofloxacin against Pseudomonas aeruginosa growing in a biofilm. Antimicrob Agents Chemother 1995; 39: 1038-44.
47. Mikuniya T, Kato Y, Ida T et al. Treatment of Pseudomonas aeruginosa biofilms with a combination of fluoroquinolones and fosfomycin in a rat urinary tract infection model. J Infect Chemother 2007; 13: 285-90.
48. Marchese A, Bozzolasco M, Gualco L et al. Effect of fosfomycin alone and in combination with N-acetylcysteine on E. coli biofilms. Int J Antimicrob Agents 2003; 22 Suppl 2: 95-100.
49. Borsari AG, Bucher B, Brazzola P et al. Susceptibility of Escherichia coli strains isolated from outpatient children with community-acquired urinary tract infection in southern Switzerland. Clin Ther 2008; 30: 2090-5.
50. Romero R, Oyarzun E, Mazor M et al. Meta-analysis of the relationship between asymptomatic bacteriuria and preterm delivery/low birth weight. Obstet Gynecol 1989; 73: 576-82.
51. Dore-Bergeron MJ, Gauthier M, Chevalier I et al. Urinary tract infections in 1- to 3-month-old infants: ambulatory treatment with intravenous antibiotics. Pediatrics 2009; 124: 16-22.
52. Maraki S, Samonis G, Rafailidis PI et al. Susceptibility of urinary tract bacteria to fosfomycin. Antimicrob Agents Chemother 2009; 53: 4508-10.
53. Falagas M, Kastoris A, Kapaskelis A et al. Fosfomycin for the treatment of multidrug-resistant Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010; 10 Suppl 1: 43-50.
54. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050717s005lbl.pdf.
55. Mayama T, Yokota M, Shimatani I et al. Analysis of oral fosfomycin calcium (Fosmicin) side-effects after marketing. Int J Clin Pharmacol Ther Toxicol 1993; 31: 77-82.